Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clin...

Full description

Bibliographic Details
Main Authors:	Goyvaerts, C, De Groeve, K, Dingemans, J, Van Lint, S, Robays, L, Heirman, C, Reiser, J, Zhang, X-Y, Thielemans, K, De Baetselier, P, Raes, G, Breckpot, K
Format:	Online
Language:	English
Published:	Nature Publishing Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520013/

id	pubmed-3520013
recordtype	oai_dc
spelling	pubmed-35200132012-12-12 Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells Goyvaerts, C De Groeve, K Dingemans, J Van Lint, S Robays, L Heirman, C Reiser, J Zhang, X-Y Thielemans, K De Baetselier, P Raes, G Breckpot, K Original Article Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types. Nature Publishing Group 2012-12 2012-01-12 /pmc/articles/PMC3520013/ /pubmed/22241177 http://dx.doi.org/10.1038/gt.2011.206 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Goyvaerts, C De Groeve, K Dingemans, J Van Lint, S Robays, L Heirman, C Reiser, J Zhang, X-Y Thielemans, K De Baetselier, P Raes, G Breckpot, K
spellingShingle	Goyvaerts, C De Groeve, K Dingemans, J Van Lint, S Robays, L Heirman, C Reiser, J Zhang, X-Y Thielemans, K De Baetselier, P Raes, G Breckpot, K Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
author_facet	Goyvaerts, C De Groeve, K Dingemans, J Van Lint, S Robays, L Heirman, C Reiser, J Zhang, X-Y Thielemans, K De Baetselier, P Raes, G Breckpot, K
author_sort	Goyvaerts, C
title	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
title_short	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
title_full	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
title_fullStr	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
title_full_unstemmed	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
title_sort	development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells
description	Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.
publisher	Nature Publishing Group
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520013/
_version_	1611939760329195520

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Similar Items